Abstract

Gastric cancer is a malignant tumor with high morbidity and mortality, which is a serious threat to human life and health. At present, the diagnosis and course monitoring of gastric cancer mainly rely on gastroscopic biopsy and CT, but their invasiveness and delay limit their clinical value. Gastric cancer patients urgently need a real-time, accurate, non-invasive diagnosis and course monitoring method. Circulating tumor DNA(ctDNA) is single or double stranded DNA released into body fluid by tumor cells, which contains the same genetic mutations as the original tumor cells. It is also one of the newly emerged biological markers. With the emergence and development of next-generation sequencing(NGS) technology, the sensitivity and specificity of ctDNA detection continue to increase, and it is gradually becoming a new choice for tumor diagnosis and disease course monitoring. In this paper, the current application of the next-generation sequencing technology detecting ctDNA in diagnosis and treatment of gastric cancer was discussed.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.